학술논문

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
Document Type
Article
Source
In The Lancet Oncology August 2019 20(8):1083-1097
Subject
Primary Research
Articles
Language
ISSN
1470-2045